Selling, trading, flipping, shorting, around a core position is fine. All the money I make from selling, I put right back into the stock a couple days later. This stock is very predictable. For example, 99% of conference days, the stock goes down. So it has been pretty safe to sell the morning of a conference up until this point and buy back in a couple days later for a big gain in shares. Also, news general never comes out on a Thursday or Friday so generally pretty safe to buy/sell. I should be pretty locked in now though for the month of July and I do not see myself selling anymore the next month unless a really good opportunity comes up.
I am just sitting on a large long position hoping for $1 range in the not too distant future. Lympro is the short term key here and can achieve that in my opinion with good data, US partner, revenue guidance, and ex-US strategy. Eltoprazine is underrated in the medium term. However, MANF is going to give a new meaning to 'disruptive'.